QPPV.COM KNOWLEDGE ASSESSMENT

Pharmacovigilance in Older People: Geriatric Considerations Knowledge Assessment

Test your understanding of the concepts covered by Pharmacovigilance in Older People: Geriatric Considerations.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which approach is most appropriate when selecting age categories for a safety analysis?

Always use one broad category covering everyone aged 65 years and above. Always divide older people into as many narrow age bands as possible. Select categories according to the safety question while avoiding unnecessary instability or loss of clinically relevant patterns. Avoid age-stratified analysis because age cannot modify risk.

Question 2 of 10 Which responsibility remains with the MAH when specialist geriatric analysis is outsourced?

No responsibility remains once the vendor has received the data. The MAH must retain oversight of the pharmacovigilance system, understand significant findings and ensure appropriate actions are implemented. The vendor becomes the regulatory owner of the product benefit-risk profile. The MAH is responsible only for collecting patients' chronological ages.

Question 3 of 10 Which statement best distinguishes implementation from effectiveness of a risk-minimisation measure?

Distribution of educational material demonstrates that the safety objective was achieved. Implementation concerns whether the measure was delivered, whereas effectiveness concerns whether the targeted safety outcome or behaviour changed. Effectiveness is established whenever a measure is included in an RMP. Implementation and effectiveness are identical endpoints.

Question 4 of 10 What is the main limitation of interpreting a larger number of spontaneous reports in older people as evidence of increased medicine-related risk?

Spontaneous reports provide a reliable incidence denominator for every age group. Older people may have greater medicine exposure, healthcare contact and reporting opportunity, so report counts alone do not estimate relative risk. Older people are not permitted to submit spontaneous reports. Report counts are valid only when no concomitant medicines are used.

Question 5 of 10 Which interpretation best reflects age-related pharmacodynamic change?

An adverse event in an older patient necessarily reflects higher plasma exposure. Older patients may experience stronger or more consequential effects at similar exposure because sensitivity or physiological reserve has changed. Pharmacodynamic sensitivity is identical across all age groups if the dose is identical. Pharmacodynamic changes affect only medicines acting on the liver.

Question 6 of 10 Which information is particularly important when evaluating a report of confusion or delirium in an older patient?

Only the patient's chronological age and sex. The timing, baseline cognition, concomitant medicines, acute illness and competing neurological explanations. Only whether the suspected medicine has ever been associated with headache. The presence of a prescription without determining how the medicine was taken.

Question 7 of 10 Which example best demonstrates that formulation and usability can independently influence medicine safety?

A medicine has a well-characterised receptor target. A large tablet and unclear instructions increase swallowing or dosing errors despite the active substance being unchanged. A medicine is prescribed for a disease common in older people. A patient has a higher chronological age than the clinical-trial population.

Question 8 of 10 Which finding would most directly raise concern about confounding by indication?

The outcome is also a known complication of the disease for which the medicine is prescribed. The patient used a child-resistant container. The medicine was taken at the prescribed dose. The event occurred after a formulation change.

Question 9 of 10 Which evidence would be most useful for estimating whether an event occurs more often in older users of a medicine?

The absolute number of spontaneous reports by age alone. Exposure estimates, a suitable comparison population and a clearly defined outcome. A list of all medicines authorised for older people. A single detailed case report without information on exposure.

Question 10 of 10 Which conclusion is most appropriate when evidence suggests a risk is particularly important in a defined subgroup of frail older patients?

All patients above a chronological age threshold must receive the same restriction. The finding should be evaluated for proportionate risk-management, product-information, monitoring or communication measures targeted to the actual mechanism and subgroup. No action is possible because there is no dedicated geriatric GVP chapter. The risk should be managed only by sending general educational material.

Pharmacovigilance in Older People: Geriatric Considerations Knowledge Assessment

Cookie Settings